The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
Open accessAbstract
Fibrillar amyloid-beta (Aβ) is found in the brains of many cognitively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Aβ burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Aβ burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) ε4 allele. The 8 ε4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Aβ was significantly associated with APOE ε4 carrier status and ε4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Aβ burden in cognitively normal older people is associated with APOE ε4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Aβ accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Aβ, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Aβ imaging in primary prevention trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing a transgenic mouse model of AD that has high levels of human Aβ in the brain with human APOE targeted replacement mice demonstrated age-dependent and APOE isoform-dependent (E4>>E3>E2) Aβ deposition and amyloid burden in the brain in a manner that recapitulates the human condition observed in pre-symptomatic elderly APOE4 carriers as well as AD patients.18–21”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the amyloid deposition spreads, and the disease pathogenesis progressively involves a broad region of the brain”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The association of the APOE4 isoform with amyloid deposition has been well established in human studies, where APOE4 carriers exhibit higher A β plaque burden and earlier onset of amyloid positivity compared with non-carriers 35 -37 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE status has been found to modulate the onset of extracellular amyloid plaque deposition, one of the key pathognomonic features of the disease (6, 7).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the APOE ε4 allele increases brain amyloid burden assessed by PIB-PET imaging in a gene dose-dependent manner (6).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [6]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE isoform-dependent amyloid deposition has been consistently observed in humans and Aβ depositing mouse models (Holtzman et al., 2000; Bales et al., 2009; Reiman et al., 2009; Morris et al., 2010).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Reiman et al., 2009
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ε4 allele increased brain amyloid burden in a dose-dependent manner in normal elderly individuals and in mild cognitive impairment patients [93,94].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [93]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This finding has now been confirmed more directly in a study that showed cognitively normal subjects had an ε4 dose-dependent increase in fibrillar Aβ burden in brain as detected with an amyloid imaging agent (Reiman et al., 2009).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Reiman et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This possibility has remained unaddressed, because case–control studies without neuropathological or biomarker assessments of AD may have underestimated the impact of APOE genotypes on Alzheimer’s dementia ORs due to the confounding effects of APOE genotypes on the percentages of neuropathologically misclassified cases and controls8–10.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Due to the prioritized ascertainment of those cases who met the clinical and neuropathological criteria for Alzheimer’s dementia and those unimpaired controls without AD, the number of misclassified cases and controls available through the AD Genetics Consortium12 is much smaller than our estimated number of neuropathologically misclassified cases and controls8–11, limiting our ability to clarify”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In a previous autopsy study, we found that 25% of persons with the clinical diagnosis of mild-to-moderate Alzheimer’s dementia lacked at least moderately frequent neuritic plaques, one of the cardinal features of AD, including 37% of APOE4 non-carriers and 13% of carriers, findings that are consistent with those in living patients9,10.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Co-planar stereotaxic atlas of the human brain
Laitinen, L. (1989) · Clinical Neurology and Neurosurgery · doi:10.1016/0303-8467(89)90128-5 · Cited by 7,565
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“The APOE 4 allele is associated with increased cerebral and vascular A deposition in AD (25), and the ApoE E4 isoform is associated with increased A binding, fibrillization, and cerebral and vascular A deposition (13, 26), as well as with decreased ApoE-mediated A clearance and degradation (27–29).”
BackgroundRestriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Cited by
Sorted by citations
Items 401–500 of 787
Chiang, G. C.-Y., Insel, P. S., Tosun, D., Schuff, N. W., Truran‐Sacrey, D., Raptentsetsang, S. T., Thompson, P. M., Reiman, E. M., Jack, C. R., Fox, N. C., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.010 · Cited by 31
Self-citationByun, M. S., Kim, H. J., Yi, D., Choi, H. J., Baek, H., Lee, J. H., Choe, Y. M., Sohn, B. K., Lee, J., Lee, Y., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.07.004 · Cited by 31
Ko, K., Byun, M. S., Yi, D., Lee, J. H., Kim, C. H., & Lee, D. Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00070 · Cited by 31
Galle, S. A., van der Spek, A., Drent, M. L., Brugts, M. P., Scherder, E., Janssen, J. A. M. J. L., Ikram, M. A., & van Duijn, C. M. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00020 · Cited by 30
Reimand, J., de Wilde, A., Teunissen, C. E., Zwan, M. D., Windhorst, A. D., Boellaard, R., Barkhof, F., van der Flier, W. M., Scheltens, P., van Berckel, B. N. M., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0561-5 · Cited by 31
Snellman, A., Ekblad, L. L., Tuisku, J., Koivumäki, M., Ashton, N. J., Lantero‐Rodriguez, J., Karikari, T. K., Helin, S., Bucci, M., Löyttyniemi, E., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01209-6 · Cited by 31
Aschenbrenner, A. J., Balota, D. A., Tse, C., Fagan, A. M., Holtzman, D. M., Benzinger, T. L. S., & Morris, J. C. (2014) · Neuropsychology · doi:10.1037/neu0000133 · Cited by 32
Failing Compensatory Mechanisms During Working Memory in Older Apolipoprotein E-ε4 Healthy Adults
Filbey, F. M., Chen, G., Sunderland, T., & Cohen, R. M. (2010) · Brain Imaging and Behavior · doi:10.1007/s11682-010-9097-9 · Cited by 34
Yu, L., Petyuk, V., Tasaki, S., Boyle, P. A., Gaiteri, C., Schneider, J. A., Jager, P. L. D., & Bennett, D. A. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0834 · Cited by 30
Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study
Shi, Z., Fu, L., Zhang, N., Zhao, X., Liu, S., Zuo, C., Cai, L., Wang, Y., Gao, S., Ai, L., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.240325 · Cited by 31
The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimer’s Disease
Xia, Q., Yang, X., Shi, J., Liu, Z., Peng, Y., Wang, W., Li, B., Zhao, Y., Xiao, J., Huang, L. F., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02385-y · Cited by 32
Villemagne, V. L., & Rowe, C. C. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211000895 · Cited by 30
Suon, S., Zhao, J. J., Villarreal, S. A., Anumula, N., Liu, M., Carangia, L. M., Renger, J. J., & Zerbinatti, C. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-44 · Cited by 31
Alexopoulos, P., Tsolakidou, A. F., Roselli, F., Arnold, A., Grimmer, T., Westerteicher, C., Leante, M. R., Förstl, H., Livrea, P., Kurz, A., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.04.009 · Cited by 31
Association Between Serum Triglycerides and Cerebral Amyloidosis in Cognitively Normal Elderly
Choi, H. J., Byun, M. S., Yi, D., Choe, Y. M., Sohn, B. K., Baek, H., Lee, J. H., Kim, H. J., Han, J., Yoon, E. J., et al. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.03.001 · Cited by 30
Calderón‐Garcidueñas, L., Hernández-Luna, J., Aiello-Mora, M., Brito-Aguilar, R., Evelson, P., Villarreal-Ríos, R., Torres‐Jardón, R., Ayala, A., & Mukherjee, P. S. (2023) · Biomolecules · doi:10.3390/biom13060927 · Cited by 28
Shine, J. P., Hodgetts, C. J., Postans, M., Lawrence, A. D., & Graham, K. S. (2015) · Scientific Reports · doi:10.1038/srep16322 · Cited by 30
Neuropathologic features of TOMM40 '523 variant on late‐life cognitive decline
Yu, L., Lutz, M. W., Farfel, J. M., Wilson, R. S., Burns, D. K., Saunders, A. M., Jager, P. L. D., Barnes, L. L., Schneider, J. A., & Bennett, D. A. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.05.002 · Cited by 29
Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease
Whitwell, J. L., Tosakulwong, N., Weigand, S. D., Graff‐Radford, J., Ertekin‐Taner, N., Machulda, M. M., Duffy, J. R., Schwarz, C. G., Senjem, M. L., Jack, C. R., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.012 · Cited by 29
Jett, S., Dyke, J. P., Andy, C., Schelbaum, E., Jang, G., Boneu, C., Pahlajani, S. S., Diaz, I., Brinton, R. D., & Mosconi, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-26573-5 · Cited by 29
Yi, D., Lee, Y., Byun, M. S., Lee, J. H., Ko, K., Sohn, B. K., Choe, Y. M., Choi, H. J., Baek, H., Sohn, C., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0411-x · Cited by 31
Longitudinal cognitive decline in the AIBL cohort: The role of APOE ε4 status
Albrecht, M. A., Szoeke, C. E. I., Maruff, P. T., Savage, G. R., Lautenschlager, N. T., Ellis, K. A., Taddei, K., Martins, R. N., Masters, C. L., Ames, D. J., et al. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.06.008 · Cited by 30
Amyloid PET Ligands for Dementia
Villemagne, V. L., & Rowe, C. C. (2010) · PET Clinics · doi:10.1016/j.cpet.2009.12.008 · Cited by 31
van Dyck, C. H., Mecca, A. P., O’Dell, R. S., Bartlett, H. H., Diepenbrock, N. G., Huang, Y., Hamby, M. E., Grundman, M., Catalano, S. M., Caggiano, A. O., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01382-2 · Cited by 29
Amyloid-Independent Amnestic Mild Cognitive Impairment and Serum Apolipoprotein A1 Levels
Choi, H. J., Seo, E. H., Yi, D., Sohn, B. K., Choe, Y. M., Byun, M. S., Lee, J. M., Woo, J. I., & Lee, D. Y. (2015) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.06.004 · Cited by 27
Crawford, J. R., Bjorklund, N. L., Taglialatela, G., & Gomer, R. H. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0674-0 · Cited by 28
Hinrichs, A. L., Mintun, M. A., Head, D. M., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Goate, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.012 · Cited by 28
Association of carotid and intracranial stenosis with Alzheimer’s disease biomarkers
Kang, K. M., Byun, M. S., Lee, J. H., Yi, D., Choi, H. J., Lee, E., Lee, Y., Lee, J., Kim, Y. K., Sohn, B. K., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00675-6 · Cited by 29
Huang, Y., Ma, Y., Gao, P., Wang, Z., Huang, L., Hou, J., Tan, L., & Yu, J. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01217-6 · Cited by 29
Forlenza, O. V., Diniz, B. S., Teixeira, A. L., Stella, F., & Gattaz, W. F. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2012-3505 · Cited by 31
Rast, P., Kennedy, K. M., Rodrigue, K. M., Robinson, P. R., Gross, A. L., McLaren, D. G., Grabowski, T., Schaie, K. W., & Willis, S. L. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx099 · Cited by 30
Prognostic plasma protein panel for Aβ deposition in the brain in Alzheimer’s disease
Park, J., Han, S.-H., Lee, H., Jeong, H., Byun, M. S., Bae, J., Kim, H., Lee, D. Y., Yi, D., Shin, S. A., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101690 · Cited by 27
Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases
McAlary, L., Plotkin, S. S., & Cashman, N. R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00657-9 · Cited by 26
Shaffer, R. M., Li, G., Adar, S. D., Keene, C. D., Latimer, C. S., Crane, P. K., Larson, E. B., Kaufman, J. D., Carone, M., & Sheppard, L. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201005 · Cited by 27
Prospects of Saffron and its Derivatives in Alzheimer’s Disease
Zandi, N., Pazoki, B., Roudsari, N. M., Lashgari, N., Jamshidi, V., Momtaz, S., Abdolghaffari, A. H., & Akhondzadeh, S. (2021) · Archives of Iranian Medicine · doi:10.34172/aim.2021.35 · Cited by 25
Recent Advances in Imaging Alzheimer's Disease
Braskie, M. N., Toga, A. W., & Thompson, P. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129016 · Cited by 26
Initiative, T. A. D. N., Cheng, B., Zhang, D., Chen, S., Kaufer, D., & Shen, D. G. (2013) · Neuroinformatics · doi:10.1007/s12021-013-9180-7 · Cited by 27
Appraisal of Cognition in Preclinical Alzheimer’s Disease: A Conceptual Review
Knopman, D. S., & Caselli, R. J. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.5 · Cited by 29
Self-citationAging reduces glial uptake and promotes extracellular accumulation of Aβ from a lentiviral vector
Zhao, W., Zhang, J., Davis, E. G., & Rebeck, G. W. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00210 · Cited by 24
Shared Genetic Risk Factors for Late-Life Depression and Alzheimer’s Disease
Ye, Q., Bai, F., & Zhang, Z. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151129 · Cited by 26
Gagliardi, G. P., for the INSIGHT-preAD study group, Epelbaum, S., Houot, M., Bakardjian, H., Boukadida, L., Revillon, M., Dubois, B., Barba, G. D., & Corte, V. L. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180966 · Cited by 25
Ingala, S., Mazzai, L., Sudre, C. H., Salvadó, G., Brugulat-Serrat, A., Wottschel, V., Falcon, C., Operto, G., Tijms, B., Gispert, J. D., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.06.015 · Cited by 25
Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition
Ramanan, V. K., Wang, X., Przybelski, S. A., Raghavan, S., Heckman, M. G., Batzler, A. J., Kosel, M., Hohman, T. J., Knopman, D. S., Graff‐Radford, J., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa159 · Cited by 23
The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimer’s Disease Modeling
Lee, C., Willerth, S. M., & Nygaard, H. B. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101804 · Cited by 24
Ma, Y., Wu, J., Xu, W., Shen, X., Wang, H.-F., Hou, X., Cao, X., Bi, Y., Dong, Q., Feng, L., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200410 · Cited by 24
Lv, S., Zhang, Y., Lin, Y., Fang, W., Wang, Y., Li, Z., Lin, A., Dai, X., Ye, Q., Zhang, J., et al. (2023) · Aging Cell · doi:10.1111/acel.13932 · Cited by 24
Valkanova, V., & Ebmeier, K. P. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.02.016 · Cited by 27
Early detection of Alzheimer disease
Scheinin, N. M., Aalto, S., Kaprio, J. A., Koskenvuo, M., Räihä, I. J., Rokka, J., Hinkka‐Yli‐Salomäki, S., & Rinne, J. O. (2011) · Neurology · doi:10.1212/wnl.0b013e318225118e · Cited by 26
Hu, H., Tan, L., Bi, Y., Xu, W., Tan, L., Shen, X., Hou, X., Ma, Y., Dong, Q., & Yu, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01218-9 · Cited by 25
Silva‐Rudberg, J. A., Salardini, E., O’Dell, R. S., Chen, M.-K., Ra, J., Georgelos, J. K., Morehouse, M. R., Melino, K. P., Varma, P., Toyonaga, T., et al. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.08.002 · Cited by 23
Cerebrospinal fluid biomarkers of Alzheimer’s disease in cognitively healthy elderly
Glodzik, L. (2013) · Frontiers in bioscience · doi:10.2741/4170 · Cited by 25
Nuclear Localization of Apolipoprotein E4: A New Trick for an Old Protein
Rohn, T. T. (2017) · International Journal of Neurology and Neurotherapy · doi:10.23937/2378-3001/1410067 · Cited by 23
APOE ε 4 and resting‐state functional connectivity in racially/ethnically diverse older adults
Turney, I. C., Chesebro, A. G., Rentería, M. A., Lao, P. J., Beato, J. M., Schupf, N., Mayeux, R. P., Manly, J. J., & Brickman, A. M. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12094 · Cited by 25
Oikawa, N., Hatsuta, H., Murayama, S., Suzuki, A., & Yanagisawa, K. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23341 · Cited by 23
APOE and vascular disease: Sequencing and genotyping in general population cohorts
Rasmussen, K. L., Luo, J., Nordestgaard, B. G., Tybjærg-Hansen, A., & Frikke-Schmidt, R. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117218 · Cited by 22
High throughput object-based image analysis of β-amyloid plaques in human and transgenic mouse brain
Samaroo, H., Opsahl, A., Schreiber, J., O'Neill, S., Marconi, M., Qian, J., Carvajal‐Gonzalez, S., Tate, B. A., Milici, A. J., Bales, K. R., et al. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.10.003 · Cited by 24
Chronic MC-LR exposure promoted Aβ and p-tau accumulation via regulating Akt/GSK-3β signal pathway
Ma, Y., Wang, J., Xu, D., Chen, Y., & Han, X. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.148732 · Cited by 22
Cacciaglia, R., Salvadó, G., Molinuevo, J. L., Shekari, M., Falcón, C., Operto, G., Suárez‐Calvet, M., Milà‐Alomà, M., Sala, A., Rodriguez‐Vieitez, E., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01436-7 · Cited by 23
Influence of APOE Genotype on Whole-Brain Functional Networks in Cognitively Normal Elderly
Seo, E. H., Lee, D. Y., Lee, J. M., Park, J.-S., Sohn, B. K., Choe, Y. M., Byun, M. S., Choi, H. J., & Woo, J. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083205 · Cited by 24
Cacciaglia, R., Molinuevo, J. L., Falcón, C., Sánchez‐Benavides, G., Gramunt, N., Brugulat‐Serrat, A., Esteller, M., Morán, S., Fauria, K., & Gispert, J. D. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101818 · Cited by 22
Salvadó, G., Ferreira, D., Operto, G., Cumplido‐Mayoral, I., Arenaza‐Urquijo, E. M., Cacciaglia, R., Falcón, C., Vilor‐Tejedor, N., Minguillón, C., Groot, C., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12487 · Cited by 21
Let Food Be Thy Medicine: Diet, Nutrition, and Biomarkers’ Risk of Alzheimer’s Disease
Mosconi, L., & McHugh, P. F. (2015) · Current Nutrition Reports · doi:10.1007/s13668-014-0111-5 · Cited by 22
O3‐06‐05: LONGITUDINAL COGNITIVE DECLINE IN THE AIPL COHORT: THE ROLE OF APOE ɛ4 STATUS
Foster, J. K., Albrecht, M. A., Szoeke, C. E. I., Maruff, P. T., Savage, G. R., Lautenschlager, N. T., Ellis, K. A., Taddei, K., Martins, R. N., Masters, C. L., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.303 · Cited by 21
Postupna, N. O., Keene, C. D., Crane, P. K., Gonzalez‐Cuyar, L. F., Sonnen, J. A., Hewitt, J. L., Rice, S., Howard, K., Montine, K. S., Larson, E. B., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000153 · Cited by 21
Ye, Q., Su, F., Shu, H., Gong, L., Xie, C., Zhang, Z., & Bai, F. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9623-5 · Cited by 23
Berman, S. E., Clark, L. R., Rivera‐Rivera, L. A., Norton, D., Racine, A. M., Rowley, H. A., Bendlin, B. B., Blennow, K., Zetterberg, H., Carlsson, C. M., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170402 · Cited by 21
Park, J., Han, S., Byun, M. S., Yi, D., Lee, J. H., Park, K., Lee, D. Y., & Mook‐Jung, I. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00362 · Cited by 23
Metabolic Derangements Contribute to Reduced sRAGE Isoforms in Subjects with Alzheimer’s Disease
Fuller, K. N. Z., Miranda, E. R., Thyfault, J. P., Morris, J. K., & Haus, J. M. (2018) · Mediators of Inflammation · doi:10.1155/2018/2061376 · Cited by 21
Zhu, Y., Initiative, O. B. O. A. D. N., Gong, L., He, C., Wang, Q., Ren, Q., & Xie, C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190254 · Cited by 20
Midlife Lifestyle Activities Moderate APOE ε4 Effect on in vivo Alzheimer’s Disease Pathologies
Jeon, S. Y., Byun, M. S., Yi, D., Lee, J., Ko, K., Sohn, B. K., Lee, J., Ryu, S., Lee, D. W., Shin, S. A., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00042 · Cited by 24
Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer’s pathology
Hu, H., Tan, L., Bi, Y., Xu, W., Tan, L., Shen, X., Hou, X., Ma, Y., Dong, Q., & Yu, J. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51153 · Cited by 20
Cha, W.-J., Yi, D., Ahn, H., Byun, M. S., Chang, Y. Y., Choi, J.-M., Kim, K., Choi, H., Jung, G., Kang, K. M., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01417-8 · Cited by 20
Harnessing the Immune System for Treatment and Detection of Tau Pathology
Congdon, E. E., Krishnaswamy, S., & Sigurdsson, E. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132435 · Cited by 20
Sleep experiences during different lifetime periods and in vivo Alzheimer pathologies
Choe, Y. M., Byun, M. S., Yi, D., Lee, J. H., Jeon, S. Y., Sohn, B. K., Kim, Y. K., Shin, S. A., Sohn, C., Lee, Y. J., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0536-6 · Cited by 21
Li, J., Huang, Q., Qi, N., He, K., Li, S., Huang, L., Pan, F., Ren, S., Hua, F., Huang, Y. H., et al. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241230733 · Cited by 19
Plasma Leptin and Alzheimer Protein Pathologies Among Older Adults
Lee, S. H., Byun, M. S., Yi, D., Ahn, H., Jung, G., Jung, J. H., Chang, Y. Y., Kim, K. T., Choi, H., Choi, J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.9539 · Cited by 20
Neuroticism, conscientiousness, and in vivo Alzheimer pathologies measured by amyloid PET and MRI
Byun, M. S., Jung, J. H., Sohn, B. K., Yi, D., Lee, J. H., Jeon, S. Y., Lee, Y., Jung, G., Lee, J., Kim, Y. K., et al. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12983 · Cited by 23
Current insights into apolipoprotein E and the immune response in Alzheimer's disease
Lin, P. B., & Holtzman, D. M. (2024) · Immunological Reviews · doi:10.1111/imr.13414 · Cited by 19
Blood Hemoglobin, in-vivo Alzheimer Pathologies, and Cognitive Impairment: A Cross-Sectional Study
Kim, J. W., Byun, M. S., Yi, D., Lee, J. H., Jeon, S. Y., Ko, K., Joung, H., Jung, G., Lee, J., Sohn, C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.625511 · Cited by 19
Machine Learning for Brain Imaging Genomics Methods: A Review
Wang, M., Shao, W., Hao, X., & Zhang, D. (2023) · Machine Intelligence Research · doi:10.1007/s11633-022-1361-0 · Cited by 20
An Inflection Point in Gene Discovery Efforts for Neurodegenerative Diseases
Jager, P. L. D., & Bennett, D. A. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.275 · Cited by 19
Westlye, E. T., Hodneland, E., Haász, J., Espeseth, T., Lundervold, A., & Lundervold, A. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.06.072 · Cited by 20
Human apolipoprotein E glycosylation and sialylation: from structure to function
Moon, H.-J., Luo, Y., Chugh, D., & Zhao, L. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1399965 · Cited by 18
Wang, Z.-T., Li, K., Tan, C., Xu, W., Shen, X., Cao, X., Wang, P., Bi, Y., Dong, Q., Tan, L., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210140 · Cited by 18
Kim, Y. J., Cho, H., Kim, Y. J., Ki, C., Chung, S. J., Ye, B. S., Kim, H. J., Kim, J., Kim, S. T., Lee, K. H., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141773 · Cited by 18
Head circumference, apolipoprotein E genotype and cognition in the Bavarian School Sisters Study
Perneczky, R., Alexopoulos, P., Wagenpfeil, S., Bickel, H., & Kurz, A. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.01.008 · Cited by 19
Molecular Neuroimaging in Alzheimer's Disease
Matsuda, H., & Imabayashi, E. (2011) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.005 · Cited by 21
Association of aBACE1Gene Polymorphism with Parkinson’s Disease in a Norwegian Population
Lange, J., Lunde, K. A., Sletten, C., Møller, S. G., Tysnes, O., Alves, G. W., Larsen, J. P., & Maple‐Grødem, J. (2015) · Parkinson s Disease · doi:10.1155/2015/973298 · Cited by 18
Sacktor, N. C., Soldan, A., Grega, M. A., Farrington, L., Cai, Q., Wang, M., Gottesman, R. F., Turner, R. S., & Albert, M. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000194 · Cited by 16
Genetic associations of in vivo pathology influence Alzheimer’s disease susceptibility
Seo, J., Byun, M. S., Yi, D., Lee, J. H., Jeon, S. Y., Shin, S. A., Kim, Y. K., Kang, K. M., Sohn, C., Jung, G., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00722-2 · Cited by 17
Are the Effects ofAPOEɛ4 on Cognitive Function in Nonclinical Populations Age- and Gender-Dependent?
Rusted, J. M., & Carare, R. O. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.43 · Cited by 18
Smailović, U., Johansson, C., Koenig, T. W., Kåreholt, I., Graff, C., & Jelić, V. (2021) · Brain Sciences · doi:10.3390/brainsci11101359 · Cited by 16
Huang, H., Cui, G., Tang, H., Kong, L., Wang, X., Cui, C., Xiao, Q., & Ji, H. (2021) · Bioengineered · doi:10.1080/21655979.2021.2015528 · Cited by 17
RetractedSynergistic interaction of high blood pressure and cerebral beta-amyloid on tau pathology
Kim, T., Yi, D., Byun, M. S., Ahn, H., Jung, J. H., Kong, N., Kim, M. J., Jung, G., Lee, J., Lee, Y., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01149-7 · Cited by 19
Stonnington, C. M., Velgos, S. N., Chen, Y., Syed, S., Huentelman, M. J., Thiyyagura, P., Lee, W., Richholt, R., Caselli, R. J., Locke, D. E. C., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200132 · Cited by 18
Self-citationCacciaglia, R., Operto, G., Falcón, C., Gónzalez‐de‐Echávarri, J. M., Sánchez‐Benavides, G., Brugulat‐Serrat, A., Milà‐Alomà, M., Blennow, K., Zetterberg, H., Molinuevo, J. L., et al. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac239 · Cited by 19
Maarouf, C. L., Kokjohn, T. A., Walker, D. G., Whiteside, C. M., Kalback, W. M., Whetzel, A. M., Sue, L. I., Serrano, G. E., Jacobson, S. A., Sabbagh, M. N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105784 · Cited by 17
Self-citationThe effect of an APOE polymorphism on cognitive function depends on age
Shin, M., Kweon, S., Choi, J., Lee, Y. H., Nam, H., Park, K.-S., Kim, H. N., Song, H., Kim, B. C., Choi, S., et al. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7157-y · Cited by 18
NSAIDs may protect against age-related brain atrophy
Bendlin, B. B. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00035 · Cited by 17
Flanigan, M. R., Royse, S. K., Cenkner, D. P., Kozinski, K. M., Stoughton, C., Himes, M. L., Minhas, D. S., Lopresti, B. J., Butters, M. A., & Narendran, R. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01374-y · Cited by 16
Metadata
- Authors
- Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., Alexander, G. E., Klunk, W. E., Mathis, C. A., Price, J. C., Aizenstein, H. J., DeKosky, S. T., & Caselli, R. J.
- Affiliations
- Translational Genomics Research Institute (US)
- Banner - University Medical Center Phoenix (US)
- University of Arizona (US)
- Departments of iPsychiatry,
- University of Pittsburgh (US)
- Mayo Clinic in Arizona (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-04-21
- Volume
- 106
- Issue
- 16
- Pages
- 6820-6825
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2665196
- OpenAlex
- W2171346860
- Semantic Scholar
- 50d5adab23ba1a800626a6f613f94a2c667b07e4
- Cited by
- 785
- References
- 44
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 34 · 2023: 36 · 2022: 36 · 2021: 45 · 2020: 44 · 2019: 39 · 2018: 34 · 2017: 34 · 2016: 40 · 2015: 50 · 2014: 66 · 2013: 61 · 2012: 65
- FWCI
- 45.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- McKnight Foundation
- National Institute on Aging (R01AG025526, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, R01AG031581, P30AG019610, R37AG025516)
- National Institute of Mental Health (R01MH070729, R01MH057899)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- fibrillar amyloid-beta, Alzheimer's disease, APOE ε4, genetic risk, cognitively normal older adults, Pittsburgh compound B PET, family history of Alzheimer's disease, mild cognitive impairment, primary prevention
- MeSH terms
- Aged, Alzheimer Disease, Brain Mapping, Cognition, Heterozygote, Homozygote, Humans, Magnetic Resonance Imaging, Middle Aged, Neuropsychological Tests, Amyloid beta-Peptides, Gene Dosage, Genetic Predisposition to Disease, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
